Sir, A 25-year-old woman presented with a 6-month history of headaches and galactorrhea, and primary infertility of 3-year duration. Endocrine assessment revealed a modestly elevated serum prolactin level 96 ng/mL (reference range 2.5-29.2 ng/mL) and normal thyroid function. T1-weighted contrast-enhanced magnetic resonance imaging (MRI) ( Figure  1 : Panels A [cornonal] and B [sagittal] ) showed a 4 mm hypointense lesion on the right side of the gland (arrow), typical of a microadenoma. She was commenced on cabergoline 0.25 mg once a week, and shortly thereafter had spontaneous restoration of menses. At 3 months, she discontinued treatment following confirmation of pregnancy but unfortunately defaulted from endocrine follow-up. At 37-week gestation, she re-presented with recent onset, severe headaches. Her Glasgow Coma Scale score was 15/15, and there was no neurological deficit. Formal ophthalmic assessment showed preserved visual acuities and visual fields. A T2-weighted noncontrast MRI demonstrated a hyperintense lesion with a fluid level in an enlarged sella (Figure 1 : Panels C and D, arrows), consistent with a diagnosis of pituitary apoplexy.
She was immediately treated with hydrocortisone (100 mg intravenously, 8 hourly) and recommenced on cabergoline, at an increased dose of 0.5 mg daily. Forty-eight hours later, she underwent an uneventful lower segment cesarean section and delivered a healthy baby. She expressed a strong desire to breastfeed and hence cabergoline was stopped again. She continued on physiological hydrocortisone replacement, made a good recovery thereafter, and was able to successfully breastfeed. A repeat MRI (T1-weighted contrast-enhanced MRI) after 2-months postdelivery showed resolution of apoplexy but apparent persistence of the underlying microadenoma ( Figure  1 : Panels E and F, arrows). The patient continued to breastfeed and remained off cabergoline. Hydrocortisone was tapered following demonstration of normal adrenal function. Further imaging (T1-weighted contrast-enhanced MRI) at 4-month postpartum revealed complete resolution of the pituitary adenoma ( Figure 1 : Panels G and H). Serum prolactin has not been re-measured since delivery as the patient continues to breastfeed. She is otherwise eupituitary.
Pituitary apoplexy during pregnancy is a rare emergency with potentially life-threatening consequences for the mother and fetus.
[1] It should however be considered in the differential diagnosis of any pregnant woman presenting with sudden onset severe headache, especially where there is a prior history of a pituitary adenoma. [2] To the best of our knowledge, this is only the third case of gestational pituitary apoplexy arising in the context of a previous microprolactinoma. [3, 4] Potential precipitating factors for apoplexy include treatment with dopamine agonists, anticoagulation/antiplatelet therapy (including during coronary artery bypass grafting), hypertension, and pregnancy. [5] In our case, it is interesting to speculate whether the rise in estrogen levels during pregnancy caused growth of the microadenoma and predisposed to apoplexy. Early recognition of pituitary apoplexy ensures timely endocrine replacement therapy and combined ophthalmic and radiological assessments to guide further management. The decision for conservative versus medical (e.g., dopamine agonists) and/or surgical management should be taken on a case-by-case basis following multidisciplinary discussion between the endocrine, obstetric, neonatal, and neurosurgical teams. [6] Financial support and sponsorship Nil.
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There are no conflicts of interest. [1] In a well-conducted study, the authors documented a high prevalence of islet autoantibodies in fifty patients with Type 1 diabetes (T1D). The main pancreatic autoantibody, i.e., glutamic acid decarboxylase (GAD65) antibody and islet antigen-2 antibodies were detected in 78% and 30% patients, respectively. The prevalence is the highest ever reported in Indian patients with T1D. The reported prevalence in the previous Indian studies has ranged between 26% and 61%. [2, 3] The prevalence of thyroid autoantibodies was, however, similar to that of other reports. [3] While the findings of the current study are interesting and an important addition to the scarce Indian data on T1D autoimmunity, an attempt to explain such a high prevalence of islet autoantibodies is missing in the paper.
Gestational Pituitary Apoplexy
The exact reasons for the differences in the prevalence of islet autoantibodies in different patient populations of T1D are poorly understood at present. Factors such as genetic heterogeneity of the patient populations, the timing of estimation from disease onset, differences in laboratory assays and threshold limits, patient recruitment procedures, and sample size have been cited as the potential causes for the observed differences in the prevalence of autoantibodies. [4] It has been long known that a clear association between specific human leukocyte antigen haplotypes and development of islet autoantibodies exists. [5] Similar to the distinct regional variations in the prevalence of celiac autoimmunity, the variations in the prevalence of islet autoimmunity in T1D may have some association with genetic heterogeneity of patient populations across India.
The prevalence of islet autoantibodies is known to decrease with the duration of disease. The maximum positivity approaching 95% is present before the disease onset in at-risk individuals. [4] The positivity rate after the onset of T1D decreases with the progression of the disease. In this context, the information on the duration of disease at the time of estimation of islet autoantibodies is important. Furthermore, an age-wise analysis of positivity rate may help us to know whether younger patients have contributed significantly to the higher positivity. The prevalence of islet autoantibodies is higher in younger patients at the time of the diagnosis of T1D. [4] The laboratory assays used for measuring islet autoantibodies may also affect the positivity rates. The gold standard assays for islet autoantibodies measurement are radio binding, bridge-ELISA, and electrochemiluminescence immunoassays. [4] Although the radioimmunoassay used in the current study is a standard method of islet autoantibody measurement, ensuring its standardization is a problem in the developing countries unlike in the developed countries where programs such as the Islet Autoantibody Standardization Program supervised by the Immunology of Diabetes Society ensure high qualitative standards in islet autoantibody measurement. [4] The majority of Western studies use 99 th percentile or receiver operating characteristic analysis for determining the threshold limits of GAD65 assays as compared to Indian studies which generally use mean +3 standard deviation of normal values. [2, 3] When the latter method is applied to small numbers of patients as in the present study, it may limit the applicability of the findings. [2] The threshold limits used in the current study are lower than those used in the previous Indian studies [2, 3] which may have contributed to a higher frequency of GAD65 autoantibodies. It is thus important to mention how the thresholds for GAD65 autoantibodies were determined.
